It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The intestinal microbiota (IM) plays a role in the severity of alcohol-associated liver disease. Modifying severe alcohol-associated hepatitis (AH) dysbiosis improves liver injury through tryptophan (Trp) metabolites and the aryl hydrocarbon receptor (AhR). However, Trp’s effect on the IM in alcohol use disorder (AUD) patients remains unclear. Here, we used an in vitro microbiota modeling system named Minibioreactor arrays (MBRAs). Feces from AUD patients with or without AH were treated with low, normal, or high Trp concentrations, with subsequent treatment with alcohol. Microbiota composition and AhR activity were studied. We showed that microbial communities from donors were maintained in MBRAs. High and low Trp increased the abundance of pathogen Escherichia Shigella. In the absence of alcohol, Trp changed more bacteria in AUD IM compared to AH IM. Normal Trp increased the AhR activity. Overall, maintaining normal Trp levels may prevent dysbiosis in AUD or AH, pending in vivo confirmation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Microbiome and Immunosurveillance, Université Paris-Saclay, Inserm U996, Inflammation, Orsay, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
2 Université Paris Cité, INSERM U1016, Team “Mucosal Microbiota in Chronic Inflammatory Diseases”, CNRS UMR 8104, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
3 Microbiome and Immunosurveillance, Université Paris-Saclay, Inserm U996, Inflammation, Orsay, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); Hôpital Antoine-Béclère, AP-HP, Hepato-Gastroenterology and Nutrition, Clamart, France (GRID:grid.413738.a) (ISNI:0000 0000 9454 4367); Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France (GRID:grid.511339.c)
4 Université Paris Cité, INSERM U1016, Team “Mucosal Microbiota in Chronic Inflammatory Diseases”, CNRS UMR 8104, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602); Microbiome-Host Interactions, Institut Pasteur, Université Paris Cité, INSERM U1306, Paris, France (GRID:grid.508487.6)
5 Microbiome and Immunosurveillance, Université Paris-Saclay, Inserm U996, Inflammation, Orsay, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France (GRID:grid.511339.c)